...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>PLOS Neglected Tropical Diseases >Rationale for Further Development of a Vaccine Based on the Circumsporozoite Protein of Plasmodium vivax
【24h】

Rationale for Further Development of a Vaccine Based on the Circumsporozoite Protein of Plasmodium vivax

机译：基于间日疟原虫环子孢子蛋白的疫苗进一步开发的理由

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Plasmodium vivax and its mosquito vectors have several distinctive characteristics that allow the transmission of this parasite in both temperate and tropical climates [1,2]. None, however, are as unique as its ability to form hypnozoites—dormant forms that reactivate periodically to cause multiple bouts of clinical malaria—that may be responsible for up to 80% of clinical episodes [1]. Unlike P. falciparum, which can be cured with blood schizonticidal drugs to eliminate the parasite reservoir, P. vivax needs to be treated with a combination of drugs that act on blood-stage as well as the dormant liver–stage parasites. Treatment of hypnozoites relies on a single line of 8-aminoquinoline drugs. Primaquine (PQ), the only approved drug for treating hypnozoites, causes severe hemolysis in individuals with glucose 6-phosphate dehydrogenase (G6PD) deficiency. In addition to G6PD-deficient individuals, the drug is contraindicated for the treatment of pregnant or breastfeeding women as well as infants. More recently, a deficiency in PQ metabolism that results in inadequate therapeutic levels of the active metabolite was identified in individuals that are poor or intermediate metabolizers of the drug, thus expanding the pool of subjects that cannot undergo radical cure needed for the treatment of P. vivax [3]. Thus, even if mass drug administration campaigns were a feasible option, because of the large groups of subjects that are not amenable to radical cure, vaccines will be an important component in the toolkit to prevent P. vivax malaria.
机译：间日疟原虫及其蚊媒具有几个独特的特征，可在温带和热带气候中传播这种寄生虫[1,2]。但是，没有一种能像次生孢子那样形成周期性的休眠体，这种休眠体会定期重新激活以引起多次临床疟疾，这可能导致多达80％的临床发作[1]。与恶性疟原虫不同，恶性疟原虫可以用血裂杀线虫药治愈以消除寄生虫库，而间日疟原虫需要用作用于血液阶段和休眠期肝阶段寄生虫的药物联合治疗。次生动物的治疗依赖于单线的8-氨基喹啉药物。 primaquine（PQ）是治疗子裂殖子的唯一获批药物，可导致6-磷酸葡萄糖脱氢酶（G6PD）缺乏的个体严重溶血。除缺乏G6PD的个体外，该药物还禁止用于孕妇或哺乳期妇女以及婴儿的治疗。最近，在药物的弱代谢者或中等代谢者中发现了PQ代谢缺陷，导致活性代谢物的治疗水平不足，从而扩大了无法接受治疗P所需的彻底治愈的受试者的范围。间体[3]。因此，即使大规模的药物管理运动是可行的选择，由于不适合进行彻底治愈的人群众多，疫苗仍将是预防间日疟原虫疟疾的工具包中的重要组成部分。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号